Combination of non-vitamin K antagonist oral anticoagulants and antiepileptic drugs
Yazarlar (3)
Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Doç. Dr. Orhan SÜMBÜL
Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Prof. Dr. Dürdane AKSOY
Tokat Gaziosmanpaşa Üniversitesi, Türkiye
| Makale Türü | Diğer (Teknik, not, yorum, vaka takdimi, editöre mektup, özet, kitap krıtiği, araştırma notu, bilirkişi raporu ve benzeri) |
| Makale Alt Türü | SCI, SSCI, AHCI, SCI-Exp dergilerinde yayınlanan teknik not, editöre mektup, tartışma, vaka takdimi ve özet türünden makale |
| Dergi Adı | EUROPEAN HEART JOURNAL |
| Dergi ISSN | 0195-668X Wos Dergi Scopus Dergi |
| Dergi Tarandığı Indeksler | SCI |
| Dergi Grubu | Q1 |
| Makale Dili | İngilizce |
| Basım Tarihi | 05-2019 |
| Cilt No | 40 |
| Sayı | 19 |
| Sayfalar | 1572 / 1572 |
| DOI Numarası | 10.1093/eurheartj/ehz091 |
| Makale Linki | https://academic.oup.com/eurheartj/article/40/19/1572/5369797 |
| Özet |
| We read with great interest the article by Steffel et al. 1 as neurology specialists. The authors performed a very useful and comprehensive guide. However, in table 5 carbamazepine, levetiracetam, phenobarbital, phenytoin, topiramate, and valproic acid have been marked with hatched dark brown, and have been reported to be contraindicated due to their effects on plasma levels of NOACs. It has been emphasized that ‘the hatched colour coding indicates no clinical or PK data available, and recommendations are based on the respective NOAC SmPC, where available or expert opinion’. 1 As mentioned in the articles 2, 3 that the authors used as reference for the table 5, the clinical relevance of these drug interactions is largely unknown since mainly data from in vitro and animal studies are available, and there are only sporadic case reports in humans. Since there are indications that substrate recognition and … |
| Anahtar Kelimeler |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| WoS | 5 |
| Google Scholar | 5 |